Updated cost-effectiveness analysis of adebrelimab plus chemotherapy for extensive-stage small cell lung cancer in China
Objective The CAPSTONE-1 trial demonstrated that adebrelimab-based immunotherapy yielded a favourable survival benefit compared with chemotherapy for patients with extensive-stage small cell lung cancer (ES-SCLC). This study aims to evaluate the cost-effectiveness of this immunotherapy in the treatm...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2024-04-01
|
| Series: | BMJ Open |
| Online Access: | https://bmjopen.bmj.com/content/14/4/e077090.full |
| _version_ | 1797220626682871808 |
|---|---|
| author | Hao Wang Yuan Xu Yujie Zhou Yunchun Long Xianhai Xie Junlin Li |
| author_facet | Hao Wang Yuan Xu Yujie Zhou Yunchun Long Xianhai Xie Junlin Li |
| author_sort | Hao Wang |
| collection | DOAJ |
| description | Objective The CAPSTONE-1 trial demonstrated that adebrelimab-based immunotherapy yielded a favourable survival benefit compared with chemotherapy for patients with extensive-stage small cell lung cancer (ES-SCLC). This study aims to evaluate the cost-effectiveness of this immunotherapy in the treatment of ES-SCLC from a healthcare system perspective in China.Design The TreeAge Pro software was used to establish a three-state partitioned survival model. Survival data came from the CAPSTONE-1 trial (NCT03711305), and only direct medical costs were included. Utility values were obtained from the published literature. Sensitivity analysis was performed to explore the robustness of the model. The cost-effectiveness of immunotherapy was investigated through scenario and exploratory analyses in various settings.Outcome measures Total costs, incremental costs, life years, quality-adjusted life-years (QALYs), incremental QALYs and incremental cost-effectiveness ratio (ICER).Results The basic analysis revealed that the adebrelimab group achieved a total of 1.1 QALYs at a cost of US$65 385, while the placebo group attained 0.78 QALYs at a cost of US$12 741. ICER was US$163 893/QALY. Sensitivity analysis confirmed that the model was robust. Results from scenario and exploratory analyses indicated that the combination of adebrelimab and chemotherapy did not demonstrate cost-effectiveness in any scenario.Conclusions From the perspective of the Chinese healthcare system, adebrelimab in combination with chemotherapy for the treatment of ES-SCLC was not economical compared with chemotherapy. |
| first_indexed | 2024-04-24T12:52:32Z |
| format | Article |
| id | doaj.art-bf2b1da042854afcb60b36c11be3bc42 |
| institution | Directory Open Access Journal |
| issn | 2044-6055 |
| language | English |
| last_indexed | 2024-04-24T12:52:32Z |
| publishDate | 2024-04-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | BMJ Open |
| spelling | doaj.art-bf2b1da042854afcb60b36c11be3bc422024-04-06T03:05:11ZengBMJ Publishing GroupBMJ Open2044-60552024-04-0114410.1136/bmjopen-2023-077090Updated cost-effectiveness analysis of adebrelimab plus chemotherapy for extensive-stage small cell lung cancer in ChinaHao Wang0Yuan Xu1Yujie Zhou2Yunchun Long3Xianhai Xie4Junlin Li5Department of Pharmacy, Nanjing Drum Tower Hospital, Nanjing, ChinaDepartment of Pharmacy, Nanjing Drum Tower Hospital, Nanjing, ChinaDepartment of Respiratory and Critical Care Medicine, Nanjing Drum Tower Hospital, Nanjing, ChinaDepartment of Pharmacy, China Pharmaceutical University Nanjing Drum Tower Hospital, Nanjing, ChinaSchool of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, ChinaSchool of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, ChinaObjective The CAPSTONE-1 trial demonstrated that adebrelimab-based immunotherapy yielded a favourable survival benefit compared with chemotherapy for patients with extensive-stage small cell lung cancer (ES-SCLC). This study aims to evaluate the cost-effectiveness of this immunotherapy in the treatment of ES-SCLC from a healthcare system perspective in China.Design The TreeAge Pro software was used to establish a three-state partitioned survival model. Survival data came from the CAPSTONE-1 trial (NCT03711305), and only direct medical costs were included. Utility values were obtained from the published literature. Sensitivity analysis was performed to explore the robustness of the model. The cost-effectiveness of immunotherapy was investigated through scenario and exploratory analyses in various settings.Outcome measures Total costs, incremental costs, life years, quality-adjusted life-years (QALYs), incremental QALYs and incremental cost-effectiveness ratio (ICER).Results The basic analysis revealed that the adebrelimab group achieved a total of 1.1 QALYs at a cost of US$65 385, while the placebo group attained 0.78 QALYs at a cost of US$12 741. ICER was US$163 893/QALY. Sensitivity analysis confirmed that the model was robust. Results from scenario and exploratory analyses indicated that the combination of adebrelimab and chemotherapy did not demonstrate cost-effectiveness in any scenario.Conclusions From the perspective of the Chinese healthcare system, adebrelimab in combination with chemotherapy for the treatment of ES-SCLC was not economical compared with chemotherapy.https://bmjopen.bmj.com/content/14/4/e077090.full |
| spellingShingle | Hao Wang Yuan Xu Yujie Zhou Yunchun Long Xianhai Xie Junlin Li Updated cost-effectiveness analysis of adebrelimab plus chemotherapy for extensive-stage small cell lung cancer in China BMJ Open |
| title | Updated cost-effectiveness analysis of adebrelimab plus chemotherapy for extensive-stage small cell lung cancer in China |
| title_full | Updated cost-effectiveness analysis of adebrelimab plus chemotherapy for extensive-stage small cell lung cancer in China |
| title_fullStr | Updated cost-effectiveness analysis of adebrelimab plus chemotherapy for extensive-stage small cell lung cancer in China |
| title_full_unstemmed | Updated cost-effectiveness analysis of adebrelimab plus chemotherapy for extensive-stage small cell lung cancer in China |
| title_short | Updated cost-effectiveness analysis of adebrelimab plus chemotherapy for extensive-stage small cell lung cancer in China |
| title_sort | updated cost effectiveness analysis of adebrelimab plus chemotherapy for extensive stage small cell lung cancer in china |
| url | https://bmjopen.bmj.com/content/14/4/e077090.full |
| work_keys_str_mv | AT haowang updatedcosteffectivenessanalysisofadebrelimabpluschemotherapyforextensivestagesmallcelllungcancerinchina AT yuanxu updatedcosteffectivenessanalysisofadebrelimabpluschemotherapyforextensivestagesmallcelllungcancerinchina AT yujiezhou updatedcosteffectivenessanalysisofadebrelimabpluschemotherapyforextensivestagesmallcelllungcancerinchina AT yunchunlong updatedcosteffectivenessanalysisofadebrelimabpluschemotherapyforextensivestagesmallcelllungcancerinchina AT xianhaixie updatedcosteffectivenessanalysisofadebrelimabpluschemotherapyforextensivestagesmallcelllungcancerinchina AT junlinli updatedcosteffectivenessanalysisofadebrelimabpluschemotherapyforextensivestagesmallcelllungcancerinchina |